News Column

Thallion Delays Annual Meeting Date

Apr 23 2013 12:00AM

Marketwire

LogoTracker

MONTREAL, QUEBEC -- (Marketwired) -- 04/23/13 -- Thallion Pharmaceuticals Inc. (TSX VENTURE: TLN) ("Thallion" or "Company") today announced that it has delayed the date of its 2013 Annual General Meeting to a date which will be no later than September 27, 2013.

Thallion had originally intended to hold its Annual General Meeting before May 31, 2013. However, as Thallion advances in its previously announced strategic review process, management has come to appreciate that such process may likely result in the requirement to present various matters to shareholders for approval. Therefore, with a view to avoiding an unnecessary duplication of expenses, Thallion has obtained court approval to delay the holding of its Annual General Meeting to no later than September 27, 2013, thereby allowing for the possibility of combining the Annual General Meeting with any other meeting of shareholders that may be required as described above. A copy of such court approval may be obtained from Thallion upon request.

About Thallion Pharmaceuticals Inc.

Thallion Pharmaceuticals Inc. (TSX VENTURE: TLN) is a biotechnology company developing pharmaceutical products in the areas of infectious disease and oncology. The Company's lead clinical program Shigamabs® is a dual antibody product for the treatment of Shiga toxin-producing E. coli bacterial infections and has recently completed a Ph II clinical trial. Additional information about Thallion can be obtained at www.thallion.com.

Forward-Looking Statements

This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements reflect Thallion's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, risks relating to the outcome of the strategic review process. There are no assurances or guarantees that the process will result in any transaction or, if a transaction is undertaken, the terms or timing of such a transaction. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Thallion undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.



Contacts:
Thallion Pharmaceuticals Inc.
Michael Singer
Chief Financial Officer
(514) 940-3600
(514) 336-2343 (FAX)
info@thallion.com
www.thallion.com





Source: Marketwire


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters